Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103)
Elan Corporation, plc and Transition Therapeutics Inc. announced the achievement of the patient enrollment target for a Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer's disease. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in patients with mild to moderate Alzheimer's disease. Each patient's planned treatment period is approximately 18 months.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement with GSK
GATC acquires SOLiD DNA Sequencer from Applied Biosystems
MorphoSys Grants ImmunoGen Access to HuCAL GOLD®
CryoLife reports record second quarter revenues

Lifespin partners with the Leipzig Research Center for Civilization Diseases to obtain deep clinical insights for obesity and diabetes

DFG Forschungszentrum für Molekularphysiologie des Gehirns (CMPB) - Göttingen, Germany
Nventa assembles group of international experts for its Clinical and Scientific Advisory Board

Microscopy: Overcoming the traditional resolution limit for the fast co-tracking of molecules - Researchers have developed an innovative method to simultaneously track rapid dynamic processes of multiple molecules at the molecular scale

New tests identify very early changes in Alzheimer's disease before symptoms appear
